HLA-A02:01 - Restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A∗02:01 transgenic mice against ocular herpes

Journal of Immunology

Volumn 194, Issue 5, 2015, Pages 2232-2248

  Srivastava, Ruchi ^a   Khan, Arif A ^a   Spencer, Doran ^a   Vahed, Hawa ^a   Lopes, Patricia P ^a   Thai, Nhi Thi Uyen ^a   Wang, Christine ^a   Pham, Thanh T ^a   Huang, Jiawei ^a   Scarfone, Vanessa M ^b   Nesburn, Anthony B ^a   Wechsler, Steven L ^a,b   BenMohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD45RA ANTIGEN; CD70 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; EPITOPE; GAMMA INTERFERON; GRANZYME; GRANZYME B; GRANZYME K; HERMES ANTIGEN; HLA A2 ANTIGEN; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; TEGUMENT VIRION PHOSPHOPROTEIN 11; UNCLASSIFIED DRUG; VIRUS PROTEIN; HLA-A*02:01 ANTIGEN; PEPTIDE; UL46 PROTEIN, HUMAN HERPESVIRUS 1; VIRAL PROTEIN; VIRUS ANTIGEN;

ADULT; AGED; ALGORITHM; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; EFFECTOR CELL; FEMALE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOASSAY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SEROCONVERSION; TRANSGENIC MOUSE; ADOLESCENT; ANIMAL; ASYMPTOMATIC DISEASE; CHEMISTRY; HERPES SIMPLEX VIRUS 2; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KERATITIS, HERPETIC; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; VIROLOGY;

ADOLESCENT; ADULT; AGED; ALGORITHMS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; ASYMPTOMATIC DISEASES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOLOGIC MEMORY; KERATITIS, HERPETIC; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRAL PROTEINS;

EID: 84924402341     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402606     Document Type: Article

References (77)

1. Dervillez, X., H. Qureshi, A. A. Chentoufi, A. A. Khan, E. Kritzer, D. C. Yu, O. R. Diaz, C. Gottimukkala, M. Kalantari, M. C. Villacres, et al. 2013. Asymptomatic HLA-A∗02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J. Immunol. 191: 5124-5138.
2. Chentoufi, A. A., X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, M.Wu, X. Zhu, A. Mohebbi, S. Buus, et al. 2008. HLA-A0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180: 426-437.
3. Zhang, X., X. Dervillez, A. A. Chentoufi, T. Badakhshan, I. Bettahi, and L. Benmohamed. 2012. Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88. J. Immunol. 189: 4496-4509.
4. Samandary, S., H. Kridane-Miledi, J. S. Sandoval, Z. Choudhury, F. Langa-Vives, D. Spencer, A. A. Chentoufi, F. A. Lemonnier, and L. BenMohamed. 2014. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine. Hum. Immunol. 75: 715-729.
5. Kuo, T., C. Wang, T. Badakhshan, S. Chilukuri, and L. BenMohamed. 2014. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine 32: 6733-6745.
6. Chentoufi, A. A., L. BenMohamed, P. Van De Perre, and A. A. Ashkar. 2012. Immunity to ocular and genital herpes simplex viruses infections. Clin. Dev. Immunol. 2012: 732546.
7. + T cells from asymptomatic HSV-2 seropositive and seronegative donors. Virology 464-465: 296-311.
8. Hosken, N., P. McGowan, A. Meier, D. M. Koelle, P. Sleath, F. Wagener, M. Elliott, K. Grabstein, C. Posavad, and L. Corey. 2006. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 80: 5509-5515.
9. Dasgupta, G., A. A. Chentoufi, M. Kalantari, P. Falatoonzadeh, S. Chun, C. H. Lim, P. L. Felgner, D. H. Davies, and L. BenMohamed. 2012. Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J. Virol. 86: 4358-4369.
10. Kalantari-Dehaghi, M., S. Chun, A. A. Chentoufi, J. Pablo, L. Liang, G. Dasgupta, D. M. Molina, A. Jasinskas, R. Nakajima-Sasaki, J. Felgner, et al. 2012. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling. J. Virol. 86: 4328-4339.
11. Chentoufi, A. A., G. Dasgupta, N. D. Christensen, J. Hu, Z. S. Choudhury, A. Azeem, J. V. Jester, A. B. Nesburn, S. L. Wechsler, and L. BenMohamed. 2010. A novel HLA (HLA-A∗0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J. Immunol. 184: 2561-2571.
12. Langenberg, A. G., L. Corey, R. L. Ashley, W. P. Leong, and S. E. Straus, Chiron HSV Vaccine Study Group. 1999. A prospective study of new infections with herpes simplex virus type 1 and type 2. N. Engl. J. Med. 341: 1432-1438.
13. Dasgupta, G., and L. BenMohamed. 2011. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 29: 5824-5836.
14. Chentoufi, A. A., N. R. Binder, N. Berka, G. Durand, A. Nguyen, I. Bettahi, B. Maillère, and L. BenMohamed. 2008. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82: 11792-11802.
15. Zhang, X., A. Issagholian, E. A. Berg, J. B. Fishman, A. B. Nesburn, and L. BenMohamed. 2005. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79: 15289-15301.
16. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, et al; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347: 1652-1661.
17. Belshe, R. B., P. A. Leone, D. I. Bernstein, A. Wald, M. J. Levin, J. T. Stapleton, I. Gorfinkel, R. L. A. Morrow, M. G. Ewell, A. Stokes-Riner, et al Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366: 34-43.
18. Murphy, M. A., M. A. Bucks, K. J. O'Regan, and R. J. Courtney. 2008. The HSV-1 tegument protein pUL46 associates with cellular membranes and viral capsids. Virology 376: 279-289.
19. Muller, W. J., L. Dong, A. Vilalta, B. Byrd, K. M. Wilhelm, C. L. McClurkan, M. Margalith, C. Liu, D. Kaslow, J. Sidney, et al. 2009. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol. 90: 1153-1163.
20. Dervillez, X., C. Gottimukkala, K. W. Kabbara, C. Nguyen, T. Badakhshan, S. M. Kim, A. B. Nesburn, S. L. Wechsler, and L. Benmohamed. 2012. Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol 7: 371-378.
21. Koelle, D. M., Z. Liu, C. L. McClurkan, R. C. Cevallos, J. Vieira, N. A. Hosken, C. A. Meseda, D. C. Snow, A. Wald, and L. Corey. 2003. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc. Natl. Acad. Sci. USA 100: 12899-12904.
22. Koelle, D. M., H. B. Chen, M. A. Gavin, A. Wald, W. W. Kwok, and L. Corey. 2001. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 166: 4049-4058.
23. Oh, S., M. Terabe, C. D. Pendleton, A. Bhattacharyya, T. K. Bera, M. Epel, Y. Reiter, J. Phillips, W. M. Linehan, C. Kasten-Sportes, et al. 2004. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. 64: 2610-2618.
24. Stuber, G., G. H. Leder, W. T. Storkus, M. T. Lotze, S. Modrow, L. Székely, H. Wolf, E. Klein, K. Kärre, and G. Klein. 1994. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur. J. Immunol. 24: 765-768.
25. Betts, M. R., J. M. Brenchley, D. A. Price, S. C. De Rosa, D. C. Douek, M. Roederer, and R. A. Koup. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78.
26. Rubio, V., T. B. Stuge, N. Singh, M. R. Betts, J. S. Weber, M. Roederer, and P. P. Lee. 2003. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9: 1377-1382.
27. BenMohamed, L., R. Krishnan, C. Auge, J. F. Primus, and D. J. Diamond. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106: 113-121.
28. BenMohamed, L., R. Krishnan, J. Longmate, C. Auge, L. Low, J. Primus, and D. J. Diamond. 2000. Induction of CTL response by a minimal epitope vaccine in HLA A∗0201/DR1 transgenic mice: dependence on HLA class II restricted T (H) response. Hum. Immunol. 61: 764-779.
29. Boucherma, R., H. Kridane-Miledi, R. Bouziat, M. Rasmussen, T. Gatard, F. Langa-Vives, B. Lemercier, A. Lim, M. Bé rard, L. Benmohamed, et al. 2013. HLA-A01:03, HLA-A24:02, HLA-B08:01, HLA-B27:05, HLA-B35:01, HLA-B44:02, and HLA-C07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J. Immunol. 191: 583-593.
30. Intlekofer, A. M., A. Banerjee, N. Takemoto, S. M. Gordon, C. S. Dejong, H. Shin, C. A. Hunter, E. J. Wherry, T. Lindsten, and S. L. Reiner. 2008. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321: 408-411.
31. Zhang, X., A. A. Chentoufi, G. Dasgupta, A. B. Nesburn, M. Wu, X. Zhu, D. Carpenter, S. L. Wechsler, S. You, and L. BenMohamed. 2009. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2: 129-143.
32. Benmohamed, L., A. Thomas, M. Bossus, K. Brahimi, J. Wubben, H. Gras-Masse, and P. Druilhe. 2000. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18: 2843-2855.
33. Daubersies, P., A. W. Thomas, P. Millet, K. Brahimi, J. A. Langermans, B. Ollomo, L. BenMohamed, B. Slierendregt, W. Eling, A. Van Belkum, et al. 2000. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. 6: 1258-1263.
34. Bottius, E., L. BenMohamed, K. Brahimi, H. Gras, J. P. Lepers, L. Raharimalala, M. Aikawa, J. Meis, B. Slierendregt, A. Tartar, et al. 1996. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. J. Immunol. 156: 2874-2884.
35. McKinney, D. M., R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman. 2004. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J. Immunol. 173: 1941-1950.
36. Kessler, J. H., N. J. Beekman, S. A. Bres-Vloemans, P. Verdijk, P. A. van Veelen, A. M. Kloosterman-Joosten, D. C. Vissers, G. J. ten Bosch, M. G. Kester, A. Sijts, et al. 2001. Efficient identification of novel HLA-A(∗)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193: 73-88.
37. Sallusto, F., D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
38. Hikono, H., J. E. Kohlmeier, S. Takamura, S. T. Wittmer, A. D. Roberts, and D. L. Woodland. 2007. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J. Exp. Med. 204: 1625-1636.
39. Ladell, K., M. K. Hellerstein, D. Cesar, R. Busch, D. Boban, and J. M. McCune. 2008. Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J. Immunol. 180: 7907-7918.
40. Channappanavar, R., B. S. Twardy, and S. Suvas. 2012. Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. PLoS ONE 7: e39757.
41. Kao, C., K. J. Oestreich, M. A. Paley, A. Crawford, J. M. Angelosanto, M. A. Ali, A. M. Intlekofer, J. M. Boss, S. L. Reiner, A. S. Weinmann, and E. J. Wherry. 2011. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 12: 663-671.
42. Banerjee, A., S. M. Gordon, A. M. Intlekofer, M. A. Paley, E. C. Mooney, T. Lindsten, E. J. Wherry, and S. L. Reiner. 2010. Cutting edge: the transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J. Immunol. 185: 4988-4992.
43. Intlekofer, A. M., N. Takemoto, C. Kao, A. Banerjee, F. Schambach, J. K. Northrop, H. Shen, E. J. Wherry, and S. L. Reiner. 2007. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J. Exp. Med. 204: 2015-2021.
44. Takemoto, N., A. M. Intlekofer, J. T. Northrup, E. J. Wherry, and S. L. Reiner. 2006. Cutting edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J. Immunol. 177: 7515-7519.
45. Joshi, N. S., and S. M. Kaech. 2008. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J. Immunol. 180: 1309-1315.
46. Bernardin, F., D. Kong, L. Peddada, L. A. Baxter-Lowe, and E. Delwart. 2005. Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J. Virol. 79: 11523-11528.
47. Wang, Q. J., X. L. Huang, G. Rappocciolo, F. J. Jenkins, W. H. Hildebrand, Z. Fan, E. K. Thomas, and C. R. Rinaldo, Jr. 2002. Identification of an HLA A∗0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood 99: 3360-3366.
48. Pelte, C., G. Cherepnev, Y. Wang, C. Schoenemann, H. D. Volk, and F. Kern. 2004. Random screening of proteins for HLA-A∗0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A∗0201. J. Immunol. 172: 6783-6789.
49. Stock, A. T., C. M. Jones, W. R. Heath, and F. R. Carbone. 2006. CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant. Immunol. Cell Biol. 84: 543-550.
50. Storkus, W. J., and H. M. Zarour. 2000. Melanoma antigens recognised by CD8+ and CD4+ T cells. Forum (Genova) 10: 256-270.
51. Wallace, M. E., R. Keating, W. R. Heath, and F. R. Carbone. 1999. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J. Virol. 73: 7619-7626.
52. Hertz, T., and C. Yanover. 2007. Identifying HLA supertypes by learning distance functions. Bioinformatics 23: e148-e155.
53. Botten, J., J. Alexander, V. Pasquetto, J. Sidney, P. Barrowman, J. Ting, B. Peters, S. Southwood, B. Stewart, M. P. Rodriguez-Carreno, et al. 2006. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. 80: 8351-8361.
54. Sidney, J., S. Southwood, C. Moore, C. Oseroff, C. Pinilla, H. M. Grey, and A. Sette. 2013. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr. Protoc. Immunol. Chapter 18: Unit 18.13.
55. Harndahl, M., M. Rasmussen, G. Roder, I. Dalgaard Pedersen, M. Sørensen, M. Nielsen, and S. Buus. 2012. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur. J. Immunol. 42: 1405-1416.
56. St Leger, A. J., B. Peters, J. Sidney, A. Sette, and R. L. Hendricks. 2011. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J. Immunol. 186: 3927-3933.
57. Gilchuk, P., C. T. Spencer, S. B. Conant, T. Hill, J. J. Gray, X. Niu, M. Zheng, J. J. Erickson, K. L. Boyd, K. J. McAfee, et al. 2013. Discovering naturally processed antigenic determinants that confer protective T cell immunity. J. Clin. Invest. 123: 1976-1987.
58. BenMohamed, L., S. L. Wechsler, and A. B. Nesburn. 2002. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2: 425-431.
59. Nesburn, A. B., I. Bettahi, G. Dasgupta, A. A. Chentoufi, X. Zhang, S. You, N. Morishige, A. J. Wahlert, D. J. Brown, J. V. Jester, et al. 2007. Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection. J. Virol. 81: 7647-7661.
60. Mott, K. R., A. A. Chentoufi, D. Carpenter, L. BenMohamed, S. L. Wechsler, and H. Ghiasi. 2009. The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Invest. Ophthalmol. Vis. Sci. 50: 2903-2912.
61. Sidney, J., S. Southwood, D. L. Mann, M. A. Fernandez-Vina, M. J. Newman, and A. Sette. 2001. Majority of peptides binding HLA-A∗0201 with high affinity crossreact with other A2-supertype molecules. Hum. Immunol. 62: 1200-1216.
62. Sette, A., M. Newman, B. Livingston, D. McKinney, J. Sidney, G. Ishioka, S. Tangri, J. Alexander, J. Fikes, and R. Chesnut. 2002. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 59: 443-451.
63. Bettahi, I., A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed. 2007. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 48: 4643-4653.
64. Mackenzie, K. J., D. J. Nowakowska, M. D. Leech, A. J. McFarlane, C. Wilson, P. M. Fitch, R. A. O'Connor, S. E. Howie, J. Schwarze, and S. M. Anderton. 2014. Effector and central memory T helper 2 cells respond differently to peptide immunotherapy. Proc. Natl. Acad. Sci. USA 111: E784-E793.
65. Cornberg, M., S. C. Clute, L. B. Watkin, F. M. Saccoccio, S. K. Kim, Y. N. Naumov, M. A. Brehm, N. Aslan, R. M. Welsh, and L. K. Selin. 2010. CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. J. Immunol. 184: 2825-2838.
66. Joshi, N. S.,W. Cui, C. X. Dominguez, J. H. Chen, T. W. Hand, and S. M. Kaech. 2011. Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells. J. Immunol. 187: 4068-4076.
67. BenMohamed, L., Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32: 2274-2281.
68. Zhu, X., T. V. Ramos, H. Gras-Masse, B. E. Kaplan, and L. BenMohamed. 2004. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 34: 3102-3114.
69. Nesburn, A. B., I. Bettahi, X. Zhang, X. Zhu, W. Chamberlain, R. E. Afifi, S. L.Wechsler, and L. BenMohamed. 2006. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4: 178-187.
70. El-Awar, N., J. H. Lee, C. Tarsitani, and P. I. Terasaki. 2007. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum. Immunol. 68: 170-180.
71. Pekiner, F. N., E. Aytugar, G. Y. Demirel, and M. O. Borahan. 2013. HLA-A, B (Class I) and HLA-DR, DQ (Class II) antigens in Turkish patients with recurrent aphthous ulceration and Behçet's disease. Med. Princ. Pract. 22: 464-468.
72. Castelli, E. C., D. S. Gil, L. C. Veiga, and J. L. de Camargo. 2005. Typing class I HLA-A gene using a nested PCR-RFLP procedure. Braz. J. Med. Biol. Res. 38: 837-842.
73. Selin, L. K., M. A. Brehm, Y. N. Naumov, M. Cornberg, S. K. Kim, S. C. Clute, and R. M. Welsh. 2006. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol. Rev. 211: 164-181.
74. Selin, L. K., M. Cornberg, M. A. Brehm, S. K. Kim, C. Calcagno, D. Ghersi, R. Puzone, F. Celada, and R. M. Welsh. 2004. CD8 memory T cells: cross-reactivity and heterologous immunity. Semin. Immunol. 16: 335-347.
75. Khan, A. A., R. Srivastava, P. P. Lopes, C. Wang, T. T. Pham, J. Cochrane, N. T. Thai, L. Gutierrez, and L. Benmohamed. 2014. Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics. Hum. Vaccin. Immunother. 10: 945-963.
76. Hüfner, K., A. Horn, T. Derfuss, C. Glon, I. Sinicina, V. Arbusow, M. Strupp, T. Brandt, and D. Theil. 2009. Fewer latent herpes simplex virus type 1 and cytotoxic T cells occur in the ophthalmic division than in the maxillary and mandibular divisions of the human trigeminal ganglion and nerve. J. Virol. 83: 3696-3703.
77. Conrady, C. D., M. Zheng, D. U. Stone, and D. J. Carr. 2012. CD8+ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis. J. Immunol. 189: 425-432.